Rapid recovery of vision following early intervention with fractionated stereotactic radiotherapy for optic nerve sheath meningioma
Authors Inoue T, Okuno Y, Nishiguchi I, Ikenaga K, Mimura O
Received 20 August 2017
Accepted for publication 30 November 2017
Published 30 January 2018 Volume 2018:11 Pages 17—22
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Toshihiko Inoue,1 Yoshishige Okuno,1 Iku Nishiguchi,1 Koji Ikenaga,1 Osamu Mimura2
1Department of Radiation Oncology, Ashiya Radiotherapy Clinic Nozomi, Ashiya, Japan; 2Department of Neuro-Ophthalmological Therapeutics, Hyogo College of Medicine, Nishinomiya, Japan
Purpose: To report the outcomes of early intervention with fractionated stereotactic radiotherapy (FSRT) in a patient with primary optic nerve sheath meningioma (ONSM).
Patient and methods: A male patient in his early 40s underwent 5-beam FSRT at a prescribed dose of 50 Gy in 25 fractions over 35 days. The patient had an 11-month history of progressive visual impairment at the time of FSRT.
Results: On day 14 of treatment, the patient reported early improvement in his vision. Two weeks after the completion of FSRT, his left eye visual acuity and field recovered completely. However, the tumor regressed only slightly in the 2 years of follow-up.
Conclusion: Early intervention with FSRT for optic nerve sheath meningioma resulted in a rapid response and complete improvement of visual impairment.
Keywords: fractionated stereotactic radiotherapy, optic nerve sheath meningioma, early intervention, rapid recovery of visual impairment
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]